Kovaltry (Octocog Alfa)

Octocog alfa is a bioengineered version of human factor VIII. After intravenous administration it circulates bound to von Willebrand factor, participates in the intrinsic coagulation cascade by forming a complex with activated factor IX, and catalyzes the conversion of factor X to Xa, thereby generating thrombin and forming a stable fibrin clot.

The dosage of Kovaltry is individualized. A prescribing clinician determines the amount and frequency based on the patient’s weight, severity of factor VIII deficiency, type of bleeding episode or surgical procedure, and target plasma factor VIII activity. Dosing regimens are therefore set by the treating physician.

Safety data for Octocog alfa in pregnancy and lactation are limited. It may be used when the expected benefit to the mother outweighs potential risks to the fetus or infant. Treatment decisions should be made by the obstetrician and hematologist in consultation with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Kovaltry. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Kovaltry is a third‑generation recombinant factor VIII without animal‑derived proteins, offering a high purity profile and low risk of viral transmission. Compared with plasma‑derived concentrates, it provides consistent potency and reduced immunogenicity, though individual patient response and inhibitor development must still be monitored.

Kovaltry must be stored refrigerated between 2 °C and 8 °C. It should be kept in its original carton to protect from light, must not be frozen, and should not be shaken. If the product reaches room temperature, it may be used for a limited time as indicated in the labeling.

Kovaltry is supplied as a sterile solution for injection and is administered intravenously. The infusion is typically given through a peripheral or central line over several minutes, depending on the prescribed dose. Administration should be performed by a healthcare professional trained in intravenous infusion techniques.

The most serious adverse events include development of neutralizing antibodies (inhibitors) against factor VIII, which can render the product ineffective, and rare hypersensitivity reactions such as anaphylaxis. Thrombotic complications may also occur, especially if dosing exceeds recommended levels or in patients with pre‑existing risk factors.

Kovaltry is contraindicated in patients with known hypersensitivity to Octocog alfa or any of the excipients in the formulation. It should also be avoided in individuals who have previously experienced severe allergic reactions to other recombinant factor VIII products. Clinical judgment is required for patients with active thrombotic disease.